FDA panel votes 3-14 that Abbott (ABT) has not found right Humira dose
- Market Wrap: Durable Goods Order Outpace in Oct.; GoPro's Drone Ambitions; New Home Sales Fall Flat
- Deere & Co. (DE) Tops Q4 EPS by 26c
- After-Hours Stocks Movers 11/26: (CJES) (GPRO) Higher; (KITE) (AVNR) Lower (more...)
- U.S. Durable Goods Orders Show Surprise 0.4% Gain in Oct.; Inventories Rise to Highest-Ever Level
- GoPro (GPRO) Aims to Launch Consumer Drones Late Next Year
FDA panel votes 3-14 that Abbott (NYSE: ABT) has not found right Humira dose.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GlaxoSmithKline (GSK) Ebola Vaccine Found Safe, Produces Immune Response
- Isis Pharma (ISIS) Initiates Pivotal ISIS-SMNRx Phase 3
- ARIAD Pharma (ARIA), Specialised Therapeutics Receive Australian Approval for Iclusig
Create E-mail Alert Related CategoriesFDA, General News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!